CYP3A4 and tuberous sclerosis: In a retrospective PGx study in children with Tuberous Sclerosis Complex (TSC), the CYP3A4 polymorphism (CYP3A4*22) was shown to have an important role in the efficacy and manifestation of side effects following Everolimus treatment in these patients [45].